The immunomodulatory action of sialostatin L on dendritic cells reveals its potential to interfere with autoimmunity

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Anderson Sá-Nunes - , Universidade de São Paulo, National Institutes of Health (NIH) (Author)
  • André Bafica - , Universidade Federal de Santa Catarina (Author)
  • Lis R. Antonelli - , National Institutes of Health (NIH) (Author)
  • Eun Young Choi - , National Institutes of Health (NIH) (Author)
  • Ivo M.B. Francischetti - , National Institutes of Health (NIH) (Author)
  • John F. Andersen - , National Institutes of Health (NIH) (Author)
  • Guo Ping Shi - , Harvard University (Author)
  • Triantafyllos Chavakis - , National Institutes of Health (NIH) (Author)
  • José M. Ribeiro - , National Institutes of Health (NIH) (Author)
  • Michalis Kotsyfakis - , National Institutes of Health (NIH) (Author)

Abstract

Sialostatin L (SialoL) is a secreted cysteine protease inhibitor identified in the salivary glands of the Lyme disease vector Ixodes scapularis. In this study, we reveal the mechanisms of SialoL immunomodulatory actions on the vertebrate host. LPS-induced maturation of dendritic cells from C57BL/6 mice was significantly reduced in the presence of SialoL. Although OVA degradation was not affected by the presence of SialoL in dendritic cell cultures, cathepsin S activity was partially inhibited, leading to an accumulation of a 10-kDa invariant chain intermediate in these cells. As a consequence, in vitro Ag-specific CD4+ T cell proliferation was inhibited in a time-dependent manner by SialoL, and further studies engaging cathepsin S -/- or cathepsin L-/- dendritic cells confirmed that the immunomodulatory actions of SialoL are mediated by inhibition of cathepsin S. Moreover, mice treated with SialoL displayed decreased early T cell expansion and recall response upon antigenic stimulation. Finally, SialoL administration during the immunization phase of experimental autoimmune encephalomyelitis in mice significantly prevented disease symptoms, which was associated with impaired IFN-γ and IL-17 production and specific T cell proliferation. These results illuminate the dual mechanism by which a human disease vector protein modulates vertebrate host immunity and reveals its potential in prevention of an autoimmune disease.

Details

Original languageEnglish
Pages (from-to)7422-7429
Number of pages8
JournalJournal of Immunology
Volume182
Issue number12
Publication statusPublished - 15 Jun 2009
Peer-reviewedYes
Externally publishedYes

External IDs

Scopus 67649172594
PubMed 19494265

Keywords

Sustainable Development Goals

ASJC Scopus subject areas